期刊文献+

清髓剂量预处理异基因造血干细胞移植治疗年龄≥155岁高危恶性血液系统疾病12例临床分析

Clinical studies of myeloablative dose conditioning prior to allogeneic hematopoietic stem cell transplantation for treatment of 12 patients over 55 years with high-risk malignant blood diseases
原文传递
导出
摘要 高龄恶性血液系统疾病患者对化疗反应差、缓解率低、复发率高,且治疗过程中合并症多、治疗相关死亡率高,复杂染色体核型、继发原因等高危因素多。异基因造血干细胞移植(allo-HSCT)是有效的治疗手段,但是移植相关死亡率(TRM)高。我们采用清髓剂量预处理方案对12例年龄≥55岁高危恶性血液系统疾病患者进行allo-HSCT,现报告如下。
出处 《中华血液学杂志》 CAS CSCD 北大核心 2016年第8期708-711,共4页 Chinese Journal of Hematology
  • 相关文献

参考文献15

  • 1成人急性髓系白血病(非急性早幼粒细胞白血病)中国诊疗指南(2011年版)[J].中华血液学杂志,2011,32(11):804-807. 被引量:183
  • 2无,吴德沛,阮长耿.骨髓增生异常综合征诊断与治疗专家共识[J].中华血液学杂志,2012,33(4):347-352. 被引量:75
  • 3Sorror ML,Maris MB,Storb R,et al.Hematopoietic cell trans- plantation (HCT)- specific comorbidity index:a new tool for risk assessment before allogeneic HCT[J].Blood,2005,106(8):2912-2919.
  • 4Nazha A,Ravandi F.Acute myeloid leukemia in the elderly:do we know who should be treated and how?[J].Leuk Lymphoma,2014,55(5):979-987.
  • 5McClune BL,Weisdorf DJ,Pedersen TL,et al.Effect of age on outcome of reduced- intensity hematopoietic cell transplantation for older patients with acute myeloid leukemia in first complete remission or with myelodysplastic syndrome[J].J Clin Oncol,2009,28(11):1878-1887.
  • 6Koreth J,Aldridge J,Kim HT,et al.Reduced-intensity condition- ing hematopoietic stem cell transplantation in patients over 60 years:hematologic malignancy outcomes are not impaired in ad- vanced age[J].Biol Blood Marrow Transplant,2010,16(6):792-800.
  • 7Brunner AM,Kim HT,Coughlin E,et al.Outcomes in patients age 70 or older undergoing allogeneic hematopoietic stem cell transplantation for hematologic malignancies[J].Biol Blood Marrow Transplant,2013,19(9):1374-1380.
  • 8Sorror ML,Sandmaier BM,Storer BE,et al.Comorbidity and disease status based risk stratification of outcomes among patients with acute myeloid leukemia or myelodysplasia receiving allogeneic hematopoietic cell transplantation[J].J Clin Oncol,2007,25(27):4246-4254.
  • 9Shimoni A,Nagler A.Optimizing the conditioning regimen for allogeneic stem- ceil transplantation in acute myeloid leukemia; dose intensity is still in need[J].Best Pract Res Clin Haematol,2011,24(3):369-379.
  • 10Blaise D,Castagna L.Do different conditioning regimens really make a difference?[J].Hematology Am Soc Hematol Educ Program,2012:237-245.

二级参考文献8

  • 1Arellano ML, Langston A, Winton E, et al. Treatment of relapsed acute leukemia after allogeneie transplantation : a single center experience. Biol Blood Marrow Transplant,2007,13 : 116-123.
  • 2Prigozhina T, Gnrevitch O, Slavin S. Non-myeloablative conditioning to induce tolerance after allogeneic bone marrow transplantation in mice. EXP Hematol, 1999,27 : 1503.
  • 3Carella AM, Cavaliere M, Lerma E, et al. Autografting followed by non- myeloablative immunosuppressive chemotherapy and allogeneic peripheral-blood hematopoietie stem-cell transplantation as treatment of resistant Hodgkins' disease and non-Hedgkins' lymphoma. J Clin Oncol, 2000,18:3918-3924.
  • 4Giralt S. Reduced-intensity conditioning regimens for hematologic malignancies:what have we learned over the last 10 years? Hematology Am Soc Hematol Educ Program,2005:384-389.
  • 5Przepiorka D, Weisdorf D, Martin P, et al. 1994 consensus conference on acute GVHD grading. Bone Marrow Transplant, 1995,15:825-828.
  • 6Schulman HM, Sullivan KM, Weiden PL, et al, Chronic graft-versus-host syndrome in man. A long term clinic opathologic study of Seatle patients. Am J Med, 1980,69:204-217.
  • 7Alyea EP, Kim PIT, Ho V ,et al. Comparative outcome of non-myeloablatire and myeloablative allogeneic hematopoietic cell transplantation for patients older than 50 years of age. Blood,2005,105:1810-1814.
  • 8Bachanova V, Verneris MR, DeFor T, et al. Prolonged survival in adults with acute lymphoblastic leukemia after reduced-intensity conditioning with cord blood or sibling donor transplantation. Bleed, 2009, 113: 2902-2905.

共引文献250

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部